New approved dasatinib regimen available for clinical use.

Abstract

Dasatinib, a tyrosine kinase inhibitor of BCR-ABL, was originally approved for the second-line treatment of any-phase chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia at a dosage of 70 mg twice daily. In chronic-phase (CP) CML resistant to first-line imatinib, this regimen is more efficacious than high-dose… (More)
DOI: 10.1586/14737140.9.3.285

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.